|
| Press Releases |
|
 |
|
| Wednesday, November 26, 2025 |
|
|
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose after the FDA granted Fast Track Status. more info >> |
|
| Monday, November 17, 2025 |
|
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. more info >> |
|
| Thursday, October 30, 2025 |
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| more info >> |
|
| Tuesday, October 28, 2025 |
|
|
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma |
| more info >> |
|
| Monday, October 27, 2025 |
|
|
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease |
| more info >> |
|
| Tuesday, October 14, 2025 |
|
|
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that LEQEMBI(R) IQLIK(TM), a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease (AD) has been selected by TIME as one of the "Best Inventions of 2025" in the Medical and Healthcare category. more info >> |
|
| Wednesday, October 8, 2025 |
|
|
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIK(TM) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Friday, October 3, 2025 |
|
|
Eisai Highlights Breadth of Oncology Research at ESMO 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2025, which is taking place in Berlin, Germany from October 17 to 21. more info >> |
|
| Monday, September 29, 2025 |
|
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI(R)" (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the National Medical Products Administration (NMPA) in China. more info >> |
|
| Wednesday, September 24, 2025 |
|
|
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD) (collectively referred to as early AD) in adults who are either ApoEε4* non-carriers or heterozygous carriers. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
TruMerit與Credivera為全球醫療保健專業人員頒發首批可驗證數位憑證
May 8, 2026 23:00 HKT/SGT
|
|
|
TruMerit与Credivera为全球医疗保健专业人员颁发首批可验证数字证书
May 8, 2026 23:00 HKT/SGT
|
|
|
TruMerit and Credivera Issue First Verifiable Digital Credentials for Global Healthcare Professionals
May 8, 2026 23:00 HKT/SGT
|
|
|
エーザイとバイオジェン・インク、抗 Aβ抗体レカネマブの皮下注射製剤「LEQEMBI(R) IQLIK(TM)」の早期アルツハイマー病に対する初期療法に関する米国 FDA による優先審査の状況について
May 8, 2026 17:00: JST
|
|
|
阿斯利康與OMP在2026年Gartner供應鏈研討會暨博覽會展示「以變化速度進行規劃」
May 8, 2026 17:00 HKT/SGT
|
|
|
阿斯利康与OMP在2026年Gartner供应链研讨会暨博览会展示“以变化速度进行规划”
May 8, 2026 17:00 HKT/SGT
|
|
|
Sydney and Melbourne kick off ninth edition of PropertyGuru Asia Property Awards in Australia
May 8, 2026 14:40 HKT/SGT
|
|
|
How to Travel More Often Without Increasing Your Budget
May 8, 2026 13:00 HKT/SGT
|
|
|
CNNオリジナルシリーズ「K-Everything」初回エピソード ダニエル・デイ・キムがK-POPの国際舞台における驚異的な躍進に迫る
May 8, 2026 11:50: JST
|
|
|
How to Clear the Strait of Hormuz from the Air: UMag Solutions Launches F1Mag(R) - an Unmanned Solution for Rapid Naval Mine Detection and Anti-Submarine Warfare
May 7, 2026 20:30 HKT/SGT
|
|
|
How to Clear the Strait of Hormuz from the Air: UMag Solutions Launches F1Mag(R) - an Unmanned Solution for Rapid Naval Mine Detection and Anti-Submarine Warfare
May 7, 2026 20:30 HKT/SGT
|
|
|
How to Clear the Strait of Hormuz from the Air: UMag Solutions Launches F1Mag(R) - an Unmanned Solution for Rapid Naval Mine Detection and Anti-Submarine Warfare
May 7, 2026 20:30 HKT/SGT
|
|
|
AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026
May 7, 2026 20:00 HKT/SGT
|
|
|
豪華新能源車企賽力斯銷量數據亮眼：今年1-4月纍計超11萬輛 同比增長30%
May 7, 2026 17:43 HKT/SGT
|
|
|
豪华新能源车企赛力斯销量数据亮眼：今年1-4月累计超11万辆 同比增长30%
May 7, 2026 17:38 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
